India's merchandise exports grew by nearly 20% in July 2026, reaching $44.2 billion, despite ongoing turmoil in West Asia. This growth was attributed to market diversification and adaptive trade strategies, including re-routing shipping lines. Exports to West Asia recovered, up almost 9% year-on-year, while exports to China surged by 65% to $2.2 billion. However, the trade deficit widened to $15 billion due to slower growth in services exports (6.4%) compared to services imports (9.5%), indicating a need to boost high-value exports and competitiveness in services.
India's merchandise exports grew by 19.6% in July 2026, reaching $44.2 billion, driven by market diversification and adaptive trade strategies.
Exports to West Asia recovered significantly, showing an 8.8% increase in July 2026 compared to the previous year, despite earlier contractions.
Exports to China saw a substantial surge of 65% in July 2026, reaching $2.2 billion, and a 36% growth over April-July.
Exam Points
Merchandise exports in July 2026: $44.2 billion (19.6% growth).
Trade deficit in July 2026: $15 billion.
Exports to China in July 2026: $2.2 billion (65% growth).
India is facing a critical nationwide shortage of key chemotherapy drugs, cisplatin and carboplatin, due to soaring global platinum raw material costs, West Asia shipping disruptions restricting raw material imports, and domestic price caps. While government hospitals have managed to stabilize supplies, private hospitals are struggling, leading to treatment interruptions for cancer patients. In response, the government, through the NPPA, temporarily raised the ceiling prices of these drugs by 50% to restart domestic manufacturing, highlighting vulnerabilities in India's drug supply chains and pricing framework.
India is experiencing a critical shortage of cisplatin and carboplatin, vital chemotherapy drugs, due to multiple factors.
The primary causes include a more than doubling of platinum raw material prices, shipping constraints via West Asia, and unviable domestic price caps.
The shortage has led to treatment interruptions and delays for cancer patients, particularly in private hospitals, while government hospitals have managed to stabilize supplies.
Exam Points
Drugs in shortage: Cisplatin and Carboplatin.
NPPA raised price cap by ~50% on June 12.
Cisplatin price cap raised from ₹7.26 to ₹10.89 per ml.
The article emphasizes that trust in medicine is built not just on the doctor-patient relationship but also on institutional transparency across regulatory bodies, hospital systems, and clinical care. It highlights the need for publicly accessible regulatory frameworks, clear communication about medical costs and processes, and a culture of "Open Disclosure" when things go wrong. The author notes that India's current regulatory transparency is uneven and suggests that improving user-friendliness of digital portals and formalizing open disclosure can significantly strengthen public faith, reduce mistrust, and protect both patients and healthcare workers.
Trust in medicine is fundamentally built upon transparency within regulatory bodies, hospital systems, and clinical care, not solely on individual doctor-patient interactions.
Institutional transparency requires accessible regulatory frameworks, clear communication about medical costs and processes, and a culture of "Open Disclosure" for errors.
India's current regulatory transparency is uneven, with challenges in accessing doctor credentials and varying levels of clarity in hospital processes.
Exam Points
Doctors' Day in India: July 1.
Example of regulatory body: Tamil Nadu Medical Council (TNMC).
Example of regulatory body: National Medical Commission (NMC).
India is considering standalone AI legislation, coinciding with the EU's AI Act, which will apply from August 2, 2026. The EU Act adopts a risk-based approach, requiring "conformity assessment" for high-risk AI systems and mandating re-assessment for "substantial modifications." This poses a challenge for India's dynamic tech industry, which thrives on responsive adaptation. However, the article argues that this regulatory framework also presents an opportunity for India to build an industry around providing AI compliance services, leveraging its legal and technical professionals, and potentially becoming a participant in the EU's conformity assessment ecosystem through trade agreements.
India is contemplating its own AI legislation, aligning with the EU's AI Act which comes into force on August 2, 2026.
The EU AI Act employs a risk-based approach, requiring rigorous "conformity assessment" for high-risk AI systems and mandating re-evaluation for any "substantial modification."
This regulatory structure presents a challenge for India's tech industry, which often relies on continuous, unplanned improvements to AI systems.
Exam Points
EU AI Act entered into force: August 2024.
EU AI Act applicable from: August 2, 2026.
EU AI Act Article 43: requires "conformity assessment" for high-risk AI systems.
The Supreme Court has reaffirmed safeguards against arbitrary arrest, emphasizing that an arrested person must be properly and meaningfully informed of the grounds for arrest, as mandated by Articles 21 and 22 of the Constitution and Section 50 of the CrPC (now Section 47 of BNSS, 2023). The court's ruling in Vihaan Kumar v. State of Haryana (2025) stressed that failure to provide clear information invalidates the arrest. It also reiterated guidelines from Arnesh Kumar v. State of Bihar (2014), stating that arrests should be an exception, not routine, and must be justified by necessity, especially for offenses with punishment less than seven years. These measures aim to balance state authority with individual liberty and dignity.
The Supreme Court has reinforced that arrested persons must be properly and meaningfully informed of the grounds for their arrest, upholding constitutional rights.
Failure to provide clear information about the grounds of arrest violates Article 22(1) of the Constitution and Section 50 of the CrPC (now Section 47 of BNSS, 2023).
Arrests should not be routine; they must be justified by necessity, especially for offenses with punishment less than seven years, as per guidelines from Arnesh Kumar v. State of Bihar (2014).
Exam Points
Supreme Court case: Vihaan Kumar v. State of Haryana (2025).
Constitutional Articles: Article 21 and Article 22.
India has engaged in "reassuring" discussions with the U.S. regarding a proposed law, the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, which could impose 100% tariffs on countries, including India, that import large quantities of Russian oil. This bill, passed by the U.S. Senate, still needs House of Representatives approval to become law. India currently faces a 10% tariff on 55% of its exports to the U.S. due to a separate investigation into forced labor. The discussions aim to mitigate the impact of this potential legislation on India's trade relations.
India is in discussions with the U.S. regarding a proposed law that could impose 100% tariffs on countries importing significant Russian oil.
The proposed legislation, the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, has passed the U.S. Senate but requires approval from the House of Representatives to become law.
If enacted, these tariffs would apply to India and four other countries identified in the Bill.
Exam Points
Proposed U.S. law: Lindsey O. Graham Sanctioning Russia and Iran Act of 2026.
Proposed tariff: 100% on Russian oil imports.
Current tariff on Indian exports to U.S.: 10% on 55% of exports.
Read more
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.